RE:Replicel Ownership Of your five options, I think
1. this would be a real bummer... I give it a D+ grade. I've been a long time shareholder for 6-7+ years. My cost basis is about $0.40. I would be curious what YOFOTO would say about this...aren't they in for $0.95 a share? But if there is a buyout, it would be cheaper than it should be. they would need ~$25M+ to buy at $1/share.
2. this would be a best case. I give it this an A+ grade....but instead of buying Replicel, they buy RCH-01. Hopefully Andrew takes the profits $ and invests in the Tendon. I think that one has HUGE potential - much more than hair as there is no treatment AND it would be covered by insurances making it much more accessible to patients
3. Similar to #2, I think this is a near best case scenario, I give this an A- grade. Can the two parties work together after all this drama...I have reservations about this after recent tears and the fact they are likely going to court.
4. I hope this isn't it... while this is a positive, they now need a new Shiseido to partner with. This will take time and money...they have the time, but do they have the money... I give this a C grade.
5. this would be a "kiss your investment" goodbye. Absolute worst case scenario. Grade, F